DLB - Dolby Laboratories, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $90.33 DETAILS

Stock News

Dolby Laboratories Announces Leadership Transition

Kevin Yeaman to Retire from Dolby Marc Whitten Named President, Chief Executive Officer and Director of Dolby SAN FRANCISCO, Aug. 27, 2026 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE: DLB), today announced a new chapter in its leadership as Kevin Yeaman retires from Dolby after nearly two decades with the company and Marc Whitten is appointed President, Chief Executive Officer and a member of Dolby Laboratories' Board of Directors. After a thoughtful, long-term succession process Dolby Laboratories' Board appointed Marc to lead the company's next chapter.

Aug 27, 2026 05:00 AM • prnewswire.com

Cinemo, Dolby, and SmashLabs Bring In-Car Immersive Gaming Experiences to the Next Level

Cinemo, a global leader and one-stop-shop provider for fully integrated, innovative multi-device in-car infotainment solutions, today announced a collaboration

Aug 21, 2026 02:00 AM • gurufocus.com

Dividend Champion, Contender, And Challenger Highlights: Week August 16

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

Aug 14, 2026 02:01 PM • seekingalpha.com

Assenagon Asset Management S.A. Has $5.48 Million Position in Dolby Laboratories $DLB

Assenagon Asset Management S.A. increased its stake in shares of Dolby Laboratories (NYSE: DLB) by 88.9% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 104,202 shares of the electronics maker's stock after acquiring an additional 49,044 shares during

Aug 12, 2026 11:31 PM • defenseworld.net

Here's Why Dolby Laboratories (DLB) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Aug 12, 2026 06:46 AM • zacks.com

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

Innovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines

Aug 04, 2026 01:15 AM • globenewswire.com

Can Dolby's Fiscal Q4 Growth Outlook Overcome Licensing Volatility?

Dolby targets a sharp fiscal Q4 rebound as content deals, auto Atmos growth and licensing gains face contract-timing volatility.

Aug 03, 2026 07:11 AM • zacks.com

Is Dolby Stock Worth Buying as Growth Meets Near-Term Execution Risks?

Dolby's discounted valuation and $756 million cash balance support its long-term case as premium formats and auto licensing expand.

Aug 03, 2026 07:01 AM • zacks.com

Why Dolby Labs Stock Popped Today

Dolby beat on earnings but missed on sales last night. Both earnings and sales declined year over year -- but should improve in Q4.

Jul 31, 2026 07:02 AM • fool.com

Dolby's Q3 Earnings Beat Estimates on Lower Operating Expenses

DLB beat Q3 earnings estimates despite lower revenue, then forecast strong Q4 growth backed by video licensing, autos and new device categories.

Jul 31, 2026 05:06 AM • zacks.com

Dolby Laboratories Q3 Earnings Call Highlights

Dolby Laboratories NYSE: DLB reported third-quarter fiscal 2026 revenue of $305 million, within its prior guidance range, as strength in Dolby Atmos, Dolby Vision and imaging patents was partly offset by deal timing and foundational audio revenue.

Jul 30, 2026 10:05 PM • marketbeat.com

Dolby Laboratories (DLB) Q3 Earnings Beat Estimates

Dolby Laboratories (DLB) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.67 per share. This compares to earnings of $0.78 per share a year ago.

Jul 30, 2026 04:31 PM • zacks.com

Dolby Laboratories (DLB) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Dolby Laboratories (DLB) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Jul 30, 2026 04:01 PM • zacks.com

Dolby Laboratories, Inc. (DLB) Q3 2026 Earnings Call Transcript

Jul 30, 2026 03:43 PM • seekingalpha.com

Dolby Laboratories Reports Third Quarter 2026 Financial Results

SAN FRANCISCO, July 30, 2026 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the third quarter of fiscal 2026. "We continue to execute against our full-year objectives, and we are building momentum across several of our key growth areas," said Kevin Yeaman, President and CEO, Dolby Laboratories.

Jul 30, 2026 12:15 PM • prnewswire.com

Aristotle Global Equity Advisory Q2 2026 Portfolio Review

For the second quarter of 2026, Aristotle Capital's Global Equity WM Composite posted a total return of 6.92% pure gross of fees (6.40% net of fees), underperforming the MSCI ACWI Index, which returned 14.93%, and the MSCI World Index, which returned 13.76%. During the quarter, we sold our positions in Danaher, Dolby Laboratories, and Tokyo Century and purchased Techtronic Industries and Wal-Mart de Mexico. Munich Re, the world's largest reinsurance company, was a detractor during the quarter.

Jul 29, 2026 09:20 PM • seekingalpha.com

Dolby Laboratories Valuation Is Compelling Ahead Of Earnings

Dolby Laboratories is now undervalued after a 50%+ decline from its all-time high, trading at 18.7x FCF and 19.7x earnings. DLB's revenue growth remains choppy, but licensing—especially in Broadcast and Mobile—drives solid results and offers mid-single-digit growth potential. Expansion into automotive and increased adoption of Dolby Atmos/Vision by major platforms and automakers support future growth, with modest price increases feasible.

Jul 20, 2026 06:18 AM • seekingalpha.com

Dolby Laboratories Announces Conference Call and Webcast for Q3 Fiscal 2026 Financial Results

SAN FRANCISCO, July 14, 2026 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE: DLB), a leader in immersive entertainment experiences, will release financial results for the third quarter (Q3) fiscal year 2026 after the close of regular trading on Thursday, July 30, 2026. Members of Dolby management will lead a conference call open to all interested parties to discuss Q3 fiscal year 2026 financial results for Dolby Laboratories at 2:00 p.m.

Jul 14, 2026 12:15 PM • prnewswire.com

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

Jul 14, 2026 03:30 AM • globenewswire.com

Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain

Cognition Therapeutics is currently prioritizing zervimesine for DLB psychosis. This is after the FDA's feedback gave their planned pivotal program a clearer path. Basically, DLB psychosis has no approved therapy, and zervimesine is a promising oral once-daily drug that already has interesting Phase 2 data. CGTX's SHIMMER trial was a good start, but their next trial must confirm longer-lasting hallucination and delusion benefits.

Jun 26, 2026 06:07 AM • seekingalpha.com

Price Targets